Clinical Trials Logo

Neoplasms, Second Primary clinical trials

View clinical trials related to Neoplasms, Second Primary.

Filter by:

NCT ID: NCT02728167 Terminated - Liver Metastasis Clinical Trials

Efficacy of HIFU-AR on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy

HIFU-AR
Start date: April 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether HIFU-assisted liver resection (HIFU-AR) results in reduced blood loss compared to standard liver resection in patients with LM.This is a prospective, monocentric, randomized (1:1 ratio), comparative, open-label Phase II study.

NCT ID: NCT02700308 Terminated - Solid Tumors Clinical Trials

A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases

KYPHO-01
Start date: March 2016
Phase: Phase 2
Study type: Interventional

Conventional vertebroplasty is an effective option in the treatment of bone lesions (osteoporotic and neoplastic). It is indicated as an analgesic treatment and aims at reinforcing a compressed vertebrae or at risk of fracture. The main adverse event related to vertebroplasty use is the cement leakages that might be responsible for significant clinical impairments. Kyphoplasty is a recent alternative strategy of vertebroplasty, based on the insertion on balloon through the needle into the targeted vertebrae and then inflation of the balloon prior to cement injection into the space. In an osteoporotic setting, kyphoplasty allow reducing the incidence of cement leakage. To date, no data from randomized study are available in the population of cancer patients.

NCT ID: NCT02598427 Terminated - Clinical trials for HER2 Positive Untreated Metastatic Breast Cancer

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine how well pertuzumab and trastuzumab works in treating breast cancer that has spread to the brain. Pertuzumab and trastuzumab are treatments that stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). Pertuzumab and trastuzumab have been found to be very effective for HER2-positive breast cancer and are FDA approved for treatment of metastatic breast cancer outside of the brain when given through the vein. This suggests that pertuzumab and trastuzumab may help shrink or stabilize HER2-positive breast cancer that has spread to the brain in this research study. In this research study, the investigators are looking to see whether pertuzumab and trastuzumab will work to decrease the size of or stabilize breast cancer that has spread to the brain.

NCT ID: NCT02565433 Terminated - Neoplasm Metastases Clinical Trials

Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)

PRAMECE-1302
Start date: November 2013
Phase: N/A
Study type: Interventional

The aim of the study is to assess prospectively the impact of radiosurgery on the quality of life in patients with brain metastases.

NCT ID: NCT02429804 Terminated - Clinical trials for Metastatic Prostate Carcinoma

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Start date: April 2015
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.

NCT ID: NCT02376933 Terminated - Multiple Myeloma Clinical Trials

Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer

Start date: August 20, 2013
Phase: N/A
Study type: Interventional

Vertebral augmentation with radiotherapy to increase the functional status and quality of life for patients with vertebral body metastatic cancers.

NCT ID: NCT02354326 Terminated - Malignant Neoplasm Clinical Trials

Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer

Start date: November 7, 2014
Phase:
Study type: Observational

This clinical trial studies dual energy computed tomography (CT) in finding cancer that has spread from the original (primary) tumor to the bone (bone metastases) in patients with cancer. Diagnostic procedures, such as dual energy CT, may help find and diagnose bone metastases and may be more accurate compared to single energy CT alone.

NCT ID: NCT02279992 Terminated - Glioma Clinical Trials

Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

LevitraCarbo
Start date: March 27, 2012
Phase: Early Phase 1
Study type: Interventional

This is a randomized pilot study to investigate the ability of a phosphodiesterase-V inhibitor (vardenafil) to increase the concentration of systemically delivered chemotherapy, carboplatin, in patients with recurrent malignant gliomas or metastatic brain cancer. This study will also determine the toxicity and tolerability of a phosphodiesterase-V inhibitor (vardenafil) in combination with intravenous carboplatin for patients with recurrent malignant gliomas or metastatic brain cancer.

NCT ID: NCT02174107 Terminated - Spine Metastases Clinical Trials

Health Economics Evaluation of Percutaneous Vertebroplasty Compared to Radiation Therapy in Patients With Painful Spine Metastases.

Radiointer
Start date: April 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate cost-utility analysis in order to provide recommendations to French decision-makers between vertebroplasty and radiation therapy in Bone spine metastases. Indeed, radiation therapy is often advocated a systematic way. The object of this study would be to expand the use of vertebroplasty. Moreover, this study assess to the strategy impact on the pain control reduction and functional preservation. In fact, analgesic effect is achieved differently depending on the procedure used.Eligible patients will be recruited and registered consecutively. Patients will be randomly, This is a health-economic multicenter, prospective, randomized with stratification according to number of vertebrae to treat (1-3 vertebrae vs 4-6 vertebrae) and center : - Arm A: Percutaneous vertebroplasty - Arm B: External radiotherapy This is an open-label study. The expected total study period is 2.5 years (enrolment: 2 years, patient follow-up: 6 months). A total number of 304 patients with spine metastases will be recruited (152 patients/arm).

NCT ID: NCT02166658 Terminated - Breast Cancer Clinical Trials

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)

CaBaMet
Start date: August 2015
Phase: Phase 2
Study type: Interventional

Patients suffering from histologically or cytologically confirmed stage IV lung or breast cancer with progressive or recurrent brain metastases after prior external beam radiotherapy will receive treatment with cabazitaxel until progression of brain metastases (BM) or unacceptable toxicity.